Bafna Pharmaceuticals Ltd

NSE
BAFNAPH •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Bafna Pharmaceuticals Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
52W Low on Jun 24, 2024
5
TTM PE Ratio
Below industry Median
29.4
Price to Book Ratio
Below industry Median
2.7
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is negative
-0.8
RSI
RSI is mid-range
53.8
MFI
MFI is mid-range
32

Bafna Pharmaceuticals Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Bafna Pharmaceuticals Ltd shareholding Pattern

Promoter
88.3%
Public
11.7%
Promoter
88.3%
Public
11.7%
Promoter
88.4%
Public
11.6%
Promoter
88.7%
Public
11.3%
Promoter
90%
Public
10%
Promoter
90%
Public
10%

Bafna Pharmaceuticals Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
14
Bearish Moving Averages
2
5Day EMA
88.90
10Day EMA
88.10
12Day EMA
88.00
20Day EMA
88.20
26Day EMA
88.30
50Day EMA
88.60
100Day EMA
89.60
200Day EMA
91.70
5Day SMA
88.40
10Day SMA
87.20
20Day SMA
89.70
30Day SMA
89.40
50Day SMA
87.40
100Day SMA
90.90
150Day SMA
90.90
200Day SMA
92.20
Delivery & Volume
Resistance & Support
89.97
Pivot
Resistance
First Resistance
92.91
Second Resistance
94.47
Third Resistance
97.41
Support
First Support
88.41
Second support
85.47
Third Support
83.91
Relative Strength Index
53.78
Money Flow Index
31.95
MACD
-0.26
MACD Signal
-0.62
Average True Range
4.81
Average Directional Index
15.39
Rate of Change (21)
-3.65
Rate of Change (125)
4.33
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Bal Pharma Ltd.
190.06
81.2
132.45
Brooks Laboratories Ltd.
222.52
73.25
185.7
Lactose (India) Ltd.
-
-
-
BDH Industries Ltd.
-
-
-
Vaishali Pharma Ltd.
167.68
114.85
203.6
Quest Laboratories Ltd.
-
-
-

Bafna Pharmaceuticals Ltd Company background

Founded in: 1995
Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a. Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern. During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products. During 2006, Bafna has set up a 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. This facility has been set up as per revised Schedule M under the Drugs and Cosmetics Act, 1947. The unit has been WHO GMP certified and also ISO 9000 certified. The manufactured products in this factory catered to the markets of Srilanka, Ghana and Ukraine.Bafna was carrying on contract manufacturing for M/s Croslands Pvt. Ltd, a Mumbai based Pharmaceutical Company during the period 1994 to 2000. The companys first product was registered in Srilanka in 1995 and the company made its first export during the same year. Presently around 57 products of the company are registered in Srilanka. During the year 2000 Bafna registered 3 of its products in Lao and in the year 2006, 4 products were registered in Ukraine. During 2007, Bafna registered 1 product in Ghana. The products registered by the company cover all the therapeutic segments. In the year 2003, the Government of India granted the Export House status to the company. The company received the Best Supplier award from the Srilankan Government during 2005.After establishing itself in the non regulated market, the company decided to enter into a more lucrative and regulated market of Europe. Towards this objective, the company started construction of a new state of art facility at Grantlayon village, near Red hills, Chennai for the manufacture of Non Betalactum products in solid oral dosage form during 2005. This unit is a 100% EOU unit. The factory was completed and inaugurated on October 2, 2006. This new plant has been set up with guidelines as laid down in European GMP. The machineries installed in the new facility of the company are Programmable Logic Controller and all the contact parts are made of stainless steel. This leads to consistent quality of products produced with no contamination. The Auto Coater machinery used in the unit is imported from Korea and Camera system for detection of unfilled product is imported from USA. The company has entered into an agreement with an UK based company Somex Pharma for sale of cholesterol lowering agent products to be manufactured by Bafna at this unit. A fullscale commercial production would be commenced in the new unit once approval of MHRA is received. Presently company is validating the equipments and process at this unit and taking validation batches for trail run.The Company launched Raricap to domestic market in FY 12. It again launched three more brands namely BSF (Dietary Supplement), Molev (Antiasthamics) and Lopih (Lowering pregnancy induced hypertension) segments for women wellness. In 2022, it expanded operations and set up manufacturing facilities in Chennai, India, with UKMHRA TGA Australia accreditations, with round the year exports to prestigious Regulated Markets and Emerging markets.
Read More

Bafna Pharmaceuticals Ltd FAQs

Bafna Pharmaceuticals Ltd shares are currently priced at 91.34 on NSE and 91.08 on BSE as of 7/11/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Bafna Pharmaceuticals Ltd [BAFNAPH] share was -5.54. The Bafna Pharmaceuticals Ltd [BAFNAPH] share hit a 1-year low of Rs. 73.25 and a 1-year high of Rs. 119.

The market cap of Bafna Pharmaceuticals Ltd is Rs. 216.08 Cr. as of 7/11/2024 12:00:00 AM.

The PE ratios of Bafna Pharmaceuticals Ltd is 29.29 as of 7/11/2024 12:00:00 AM.

The PB ratios of Bafna Pharmaceuticals Ltd is 2.66 as of 7/11/2024 12:00:00 AM

You can easily buy Bafna Pharmaceuticals Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -